Recent reports detail an outbreak of Andes orthohantavirus (ANDV) involving 13 cases, including 12 confirmed and one probable, linked to an expedition cruise ship. This event highlights the potential for rapid international dissemination of infectious agents via global travel, necessitating coordinated public health responses. Clinicians should be aware of the epidemiological context of ANDV, particularly in patients with relevant travel histories, given the reported 23% case-fatality rate.1,2,3
As of 18 June 2026, a total of 13 cases of Andes orthohantavirus (12 confirmed and one probable) have been reported. This outbreak has been linked to the Dutch-flagged expedition cruise ship MV Hondius. The case-fatality rate observed in this event was 23%.1,2,3
The outbreak involved individuals from 23 nationalities, underscoring the international scope of the event. The public health response required medical evacuation, repatriation, coordinated international contact tracing, isolation, quarantine, and subsequent clinical and laboratory testing follow-up for affected individuals.1,2,3
Epidemiology of the Outbreak
All reported cases to date have been either passengers or crew members of the MV Hondius. Specifically, 10 out of 121 passengers (8%) and 3 out of 61 crew members (5%) were affected.1,2,3
Ongoing monitoring and investigations are being conducted to clarify the source of the outbreak, identify specific risk factors associated with transmission, and implement measures to prevent further spread of the virus.1,2,3
The event highlights the complex challenges in global outbreak preparedness, particularly concerning zoonotic pathogens with potential for human-to-human transmission, such as Andes orthohantavirus. The interconnectedness of global travel, exemplified by expedition cruise ships, necessitates a comprehensive One Health approach to address emerging infectious threats effectively.2
In vitro studies have demonstrated potent antiviral activity of 4'-Fluorouridine against diverse orthohantaviruses, including Andes virus. This research may inform future therapeutic strategies for ANDV.3
The Andes orthohantavirus outbreak linked to the MV Hondius cruise ship serves as a stark reminder of the rapid global dissemination potential of infectious diseases. Clinicians must maintain a high index of suspicion for unusual pathogens in patients with relevant travel histories, particularly those returning from international cruises. The reported 23% case-fatality rate for ANDV underscores the severity of this infection and the need for prompt diagnosis and management, even if specific treatments are currently limited to supportive care.
The involvement of 23 nationalities in this single event highlights the logistical complexities inherent in international contact tracing, isolation, and quarantine measures. Public health bodies, such as the UKHSA, and international organisations must continue to refine their coordinated responses for such multi-country outbreaks. The cruise industry, in particular, faces an ongoing imperative to implement robust surveillance and infection control protocols to mitigate the risk of pathogen transmission among passengers and crew.
While current treatment for ANDV remains largely supportive, the in vitro antiviral activity of 4'-Fluorouridine against Andes virus offers a potential avenue for future therapeutic development. This preclinical finding, while promising, requires extensive further research to determine its clinical utility. For now, the emphasis for clinicians must remain on early recognition, appropriate infection control, and collaboration with public health authorities to contain outbreaks and protect vulnerable populations.
- The Pivot An Andes orthohantavirus outbreak has been identified, linked to an expedition cruise ship, affecting individuals from 23 nationalities.
- The Data The outbreak involved 13 cases (12 confirmed, one probable) with a 23% case-fatality rate.
- The Action Clinicians should consider ANDV in patients presenting with compatible symptoms and a history of recent international travel, especially cruise ship travel, and be prepared for coordinated public health measures.
ART-2026-422
06/26
Cite This Article
Team TLSFE. Andes orthohantavirus outbreak linked to cruise ship travel. The Life Science Feed. Updated June 19, 2026. Accessed June 19, 2026. https://thelifesciencefeed.com/infectious-diseases/syncytial-virus-infections/news/andes-orthohantavirus-outbreak-linked-to-cruise-ship-travel.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
References
1. van den Berg OE, UKHSA ANDV Team, Severi E. Andes virus outbreak linked to expedition cruise ship travel, multi-country investigation and response, April to June 2026. Euro Surveill. 2026;31(24):2600325. doi:10.2807/1560-7917.ES.2026.31.24.2600325
2. Iwu CD, Pettan-Brewer C, Iwu-Jaja C. Beyond the cruise ship: Andes hantavirus and the neglected one health dimensions of global outbreak preparedness. Lancet Reg Health Am. 2026;54:101234. doi:10.1016/j.lana.2026.101234
3. Shrivastava-Ranjan P, McMullan LK, Whitmer SL. Potent In Vitro Antiviral Activity of 4'-Fluorouridine Against Diverse Orthohantaviruses including Andes Virus. Antiviral Res. 2026;240:106263. doi:10.1016/j.antiviral.2026.106263
